ProteinQure Secures Series A to Advance First AI-Designed Peptide Therapeutic into Clinical Trials

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

ProteinQure Inc., a biotechnology company pioneering computational peptide therapeutics, recently announced the close of an $11 million Series A financing round. The proceeds will support the initiation of the company’s first clinical trial for PQ203, a first-in-class peptide-drug conjugate for triple-negative breast cancer (TNBC), and the advancement of additional pipeline programs in neurology and nephrology.

ProteinQure is an OBIO® member, an alumnus of our BDSP™, CAAP®, and HealthMINT® programs, part of our Life Sciences Critical Technologies & Commercialization (LSCTC) Centre of Excellence, and presented at the OBIO® Investment Summit.

Arsheen Kaur
Previous

Satellos Announces Promising Phase 1b Trial Results of SAT-3247 in Adults with Duchenne Muscular Dystrophy
Next

Neuropeutics Receives the Inaugural AbbVie Biotech Innovators Award